SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.

It essentially reproduced the beneficial findings observed in DAPA-HF, with an HR for the primary endpoint of worsening HF or CV death of 0.75 (95% CI 0.65–0.86) ( Figure 2 ), although the decrease in CV or all-cause mortality did not reach statistical significance.

also in 111,027 other papers